Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/1999
09/28/1999US5958928 Pharmaceutical agents containing methotrexate derivative
09/28/1999US5958927 Psychological and nervous system disorders
09/28/1999US5958926 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
09/28/1999US5958924 Hypotensive agents, cardiovascular disorders, antiischemic agents, restenosis, anticoalugants, respiratory system disorders
09/28/1999US5958923 Treatment of nervous system disorders
09/28/1999US5958921 Method for treating depression with olanzapine
09/28/1999US5958920 Aralkyl diazabicycloalkane derivatives for CNS disorders
09/28/1999US5958919 Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
09/28/1999US5958918 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds
09/28/1999US5958917 Benzofluorene compounds, intermediates, compositions, and methods
09/28/1999US5958916 Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
09/28/1999US5958915 Antibacterial composition for oral administration
09/28/1999US5958914 For the treatment of bacterial infectious diseases
09/28/1999US5958913 Administering saturated sterol fatty acid ester
09/28/1999US5958912 Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
09/28/1999US5958911 Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides
09/28/1999US5958910 Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
09/28/1999US5958908 Sodium alendronate preparation for local administration
09/28/1999US5958905 Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
09/28/1999US5958903 Cholinesterase inhibitors
09/28/1999US5958902 Method and composition for treating sleep apnea
09/28/1999US5958901 Delivery of anionic macromolecules into cells.
09/28/1999US5958899 Polysaccharides having a high iduronic acid content
09/28/1999US5958897 Method of treating sinusitis with uridine triphosphates and related compounds
09/28/1999US5958892 2-methoxyestradiol-induced apoptosis in cancer cells
09/28/1999US5958889 Anthracycline derivatives having 4-amino-2,4,6-trideoxy-2-fluoro-mannopyranosyl group
09/28/1999US5958888 Water miscible macrolide solutions
09/28/1999US5958884 Compositions and methods for treating erectile dysfunction
09/28/1999US5958878 For treating male and non-pregnant female mammals
09/28/1999US5958872 Active survival domains of IGF-IR and methods of use
09/28/1999US5958772 Antisense inhibition of cellular inhibitor of apoptosis-1 expression
09/28/1999US5958771 Oligonucleotide from 8 to 30 nucleotides in length; for diagnosis and therapy; antitumor/antiinflammatory agents
09/28/1999US5958770 Glycoalkaloids
09/28/1999US5958767 Engraftable human neural stem cells
09/28/1999US5958726 Polynucleotide sequence of clone h84924 accession number atcc 98028; has signal sequence; for diagnosis and treatment of related diseases
09/28/1999US5958719 In intact cells containing substrate of protein tyrosine phosphatase (ptp), selective inhibition of substrate phosphorylation; incubation; activity of ptp determined by measuring the degree of phosphorylation at various times
09/28/1999US5958718 Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
09/28/1999US5958709 Processes for identifying compounds that bind to the human Y4 receptor
09/28/1999US5958683 Screening method using the RZR receptor family
09/28/1999US5958682 Virus-directed enzyme prodrug therapy for treating tumor cells consisting of a viral vector encoding bacterial nitroreductase capable of converting a prodrug into a cytotoxic drug operably linked to a promoter; and the prodrug
09/28/1999US5958457 Compositions for the delivery of antigens
09/28/1999US5958456 Comprising drug, sustained release excipient, and diluent; for oral administration
09/28/1999US5958452 Sustained release formulation comprising extruded blend of drug, hydrophobic material, hydrophobic fusible carrier divided into unit dose
09/28/1999US5958445 Organoleptically acceptable antiinflammatory agent;veterinary drug; for oral administration
09/28/1999US5958432 Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists
09/28/1999US5958427 Locally dilating blood vessels in a mammal by administering a nonpolymeric mucosally impermeant nitric oxide donor compound selected from the group of a tertiary amino or quaternary amino nitric oxide donor; male impotence, aphrodisiac
09/28/1999US5958426 Sphingolipids and a process thereto
09/28/1999US5958425 Viral vaccines
09/28/1999US5958412 Administering conjugate of antibody and anti-cancer drug, where in antibody is specific for a33 antigen for promoting colon or gastric cancer regression
09/28/1999US5958409 Administering antitumor necrosis factor antibody to the human suffering with multiple sclerosis
09/28/1999US5958400 Isolated polypeptide comprising specified amino acid sequence
09/28/1999US5958399 Vaginally administering composition comprising condensation polymer of aromatic sulfonic acid and aldehyde in physiologically acceptable carrier, prior to or after sexual intercourse
09/28/1999US5958397 Method and composition for protecting against jellyfish stings
09/28/1999US5958392 Hair connditioners comprising a blend of amphoteric addition polymers containing amine and carboxy or sulfo groups and a quaaternized vinylpyrrolidone/aminoalcohol acrylate copolymer; softness; silky feel
09/28/1999US5958383 Colored formulations for application to human skin
09/28/1999US5958379 Drug is transported to the site of action within a very short time by means of the corresponding body liquid, particularly by means of blood, in order to systemically cause the desired effect
09/28/1999US5958378 High dose liposomal aerosol formulations containing cyclosporin A or budesonide
09/28/1999US5958373 Macrocyclic polyamine ligand forms a polychelate compound with lanthanides, chromium, iron and manganese; useful for diagnostic imaging contrast
09/28/1999US5958372 Low viscosity chelating polymers for diagnostic imaging
09/28/1999CA2181351C Process and intermediates for preparing naphthyridonecarboxylic acid salts
09/28/1999CA2178021C Tobacco substitute
09/28/1999CA2157032C Isoxazolidinedione derivative and use thereof
09/28/1999CA2148417C Serine derivatives; process for preparing them and their use in cosmetic and dermatological compositions
09/28/1999CA2133503C Orally administrable opioid formulations having extended duration of effect
09/28/1999CA2017029C Composition
09/28/1999CA2014457C Pyrimidine derivatives
09/28/1999CA1340773C Anti-neoplastic, anti-viral or anti-retoviral sperime derivative
09/28/1999CA1340771C Ethylated avermectins
09/26/1999CA2264260A1 Polynucleotide molecules encoding neospora proteins
09/24/1999CA2249660A1 Novel compounds
09/24/1999CA2233033A1 Glycerol enhanced rehydration formulation
09/23/1999WO1999047925A2 Methods and compositions for diagnosis of rheumatoid arthritis
09/23/1999WO1999047708A1 Antisense modulation of pecam-1
09/23/1999WO1999047707A1 Antisense modulation of lfa-3
09/23/1999WO1999047674A2 Compounds and methods for therapy and diagnosis of lung cancer
09/23/1999WO1999047673A2 Isolated mammalian membrane protein genes and related reagents
09/23/1999WO1999047672A1 Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
09/23/1999WO1999047669A2 Human nucleic acid sequences from tissue of breast tumors
09/23/1999WO1999047653A1 Suicide gene therapy system for the treatment of brain tumours
09/23/1999WO1999047641A1 Compositions and methods for gene-based vaccines to provoke t cell responses
09/23/1999WO1999047553A2 Bacterial yeal family members as targets for antimicrobial drug design
09/23/1999WO1999047549A1 PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
09/23/1999WO1999047547A1 Cinnamic acid derivatives having cell adhesion modulating activity
09/23/1999WO1999047545A2 Inhibitors of caspases
09/23/1999WO1999047542A1 Drugs containing as the main ingredient 21-substituted glycosyl steroid compounds
09/23/1999WO1999047541A1 21-substituted glycosyl steroid compounds
09/23/1999WO1999047538A1 Cytokine receptor common gamma chain like
09/23/1999WO1999047537A1 Staphylococcus aureus spo0j2: polynucleotide and protein
09/23/1999WO1999047534A1 Compounds having immunomodulatory effects
09/23/1999WO1999047533A1 Compounds having immunomodulatory effects
09/23/1999WO1999047532A1 Crystallization of lactitol, crystalline lactitol product and use thereof
09/23/1999WO1999047529A1 Heterocyclic signal transduction inhibitors, compositions containing them
09/23/1999WO1999047524A1 Novel heterocyclic compounds
09/23/1999WO1999047522A1 Granulatimide derivatives for use in cancer treatment
09/23/1999WO1999047521A1 HYPNOTIC β-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
09/23/1999WO1999047519A1 Crystalline form of paroxetine
09/23/1999WO1999047518A1 Substituted bisindolymaleimides for the inhibition of cell proliferation
09/23/1999WO1999047517A1 Novel heterocyclic compounds
09/23/1999WO1999047512A1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
09/23/1999WO1999047508A1 Benzenesulfonamide-derivatives and their use as medicaments